Exploring Drug-Target Interactions

HITS Scientists Participate in a New European Research Project

In drug discovery it is often difficult to predict if a potential drug will be effective in humans. Recent studies have shown that the kinetics of the interaction between a drug and its target has a strong influence on the clinical success of a drug.  “Kinetics for Drug Discovery” (K4DD) brings together experts from seven European countries. They focus on optimizing binding kinetics for drug candidates with the ultimate goal of improving drug design. K4DD was launched by the Innovative Medicines Initiative (IMI), the world’s largest public-private partnership in healthcare. Coordinators are Bayer HealthCare and Leiden University of the Netherlands. HITS researchers from the Molecular and Cellular Modeling group (head: Rebecca Wade) are among the 20 partners.
Project page

About the Innovative Medicines Initiative (IMI)

IMI is the world’s largest public-private partnership in healthcare. IMI is improving the environment for pharmaceutical innovation in Europe by engaging and supporting networks of industrial and academic experts in collaborative research projects. The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115366, resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007-2013) and EFPIA companies’ in kind contribution.
More info

Press contact:
Dr. Peter Saueressig
Head of Communications
Heidelberg Institute for Theoretical Studies (HITS)
Phone: +49-6221-533245
Peter.saueressig@h-its.org
www.h-its.org
Twitter: @HITStudies